Clinical utility of quantitative immunoassays and surrogate virus neutralization tests for predicting neutralizing activity against the SARS‐CoV‐2 Omicron BA.1 and BA.5 variants-Reference-Cited by-同舟云学术

Clinical utility of quantitative immunoassays and surrogate virus neutralization tests for predicting neutralizing activity against the SARS‐CoV‐2 Omicron BA.1 and BA.5 variants

Published:2023-12 Issue:12 Volume:95 Page:
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:Journal of Medical Virology

Author:

Lee Beomki¹²^ORCID,Ko Jae‐Hoon³^ORCID,Kim Yong Chan⁴^ORCID,Baek Jin Yang³⁵^ORCID,Park Yoon Soo⁴^ORCID,Song Kyoung‐Ho⁶^ORCID,Kim Eu Suk⁶^ORCID,Lee Kyoung Hwa⁷^ORCID,Song Young Goo⁷^ORCID,Ahn Jin Young⁸^ORCID,Choi Jun Yong⁸^ORCID,Choi Won Suk⁹^ORCID,Bae Seongman¹⁰^ORCID,Kim Sung‐Han¹⁰^ORCID,Jeong Hye Won¹¹^ORCID,Lee Young Jae¹²^ORCID,Kim Hye‐Jin¹²,Choi Ju‐Yeon¹²^ORCID,Kim Byoungguk¹²^ORCID,Kim Shin‐Woo¹³^ORCID,Kwon Ki Tae¹⁴^ORCID,Peck Kyong Ran³^ORCID,Kang Eun‐Suk¹^ORCID

Affiliation:

1. Department of Laboratory Medicine and Genetics, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea

2. Graduate School of Medical Science and Engineering Korea Advanced Institute of Science and Technology (KAIST) Daejeon South Korea

3. Division of Infectious Diseases, Department of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea

4. Division of Infectious Diseases, Department of Internal Medicine Yongin Severance Hospital, Yonsei University College of Medicine Yongin South Korea

5. Asia Pacific Foundation for Infectious Diseases (APFID) Seoul South Korea

6. Department of Internal Medicine Seoul National University Bundang Hospital, Seoul National University College of Medicine Seongnam South Korea

7. Division of Infectious Diseases, Department of Internal Medicine Gangnam Severance Hospital, Yonsei University College of Medicine Seoul South Korea

8. Department of Internal Medicine Severance Hospital, Yonsei University College of Medicine Seoul South Korea

9. Division of Infectious Diseases, Department of Internal Medicine Korea University Ansan Hospital, Korea University College of Medicine Ansan South Korea

10. Department of Infectious Diseases, Asan Medical Center University of Ulsan College of Medicine Seoul South Korea

11. Department of Internal Medicine Chungbuk National University College of Medicine Cheongju South Korea

12. Division of Vaccine Clinical Research, Center for Vaccine Research National Institute of Infectious Diseases, Korea National Institute of Health Cheongju South Korea

13. Department of Internal Medicine, School of Medicine Kyungpook National University Daegu South Korea

14. Division of Infectious Diseases, Department of Internal Medicine Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University Daegu South Korea

Abstract

AbstractDeveloping new antibody assays for emerging SARS‐CoV‐2 variants is challenging. SARS‐CoV‐2 surrogate virus neutralization tests (sVNT) targeting Omicron BA.1 and BA.5 have been devised, but their performance needs to be validated in comparison with quantitative immunoassays. First, using 1749 PRNT‐positive sera, we noticed that log‐transformed optical density (OD) ratio of wild‐type (WT) sVNT exhibited better titer‐correlation with plaque reduction neutralization test (PRNT) than % inhibition value. Second, we tried 798 dilutional titration tests with 103 sera, but nonlinear correlation between OD ratio and antibody concentration limited titration of sVNT. Third, the titer‐correlations of two sVNT kits for BA.1 and two quantitative immunoassays for WT were evaluated with BA.1 and BA.5 PRNT. All tested kits exhibited a linear correlation with PRNT titers, but the sVNT kits exhibited high false‐negative rates (cPass‐BA.1 kit, 45.4% for BA.1 and 44.2% for BA.5; STANDARD F‐BA.1 kit, 1.9% for BA.1 and 2.2% for BA.5), while quantitative immunoassays showed 100% sensitivity. Linear mixed‐effects model suggested superior titer‐correlation with PRNT for quantitative immunoassays compared to sVNT kits. Taken together, the use of quantitative immunoassays for WT, rather than rapid development of new kits, would be practical for predicting neutralizing activities against emerging new variants.

Publisher

Wiley

Subject

Infectious Diseases,Virology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.29329

Reference33 articles.

1. Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates

2. World Health Organization (WHO). Statement on the update of WHO's working definitions and tracking system for SARS‐CoV‐2 variants of concern and variants of interest.2023. Accessed June 15 2023. https://www.who.int/news/item/16-03-2023-statement-on-the-update-of-who-s-working-definitions-and-tracking-system-for-sars-cov-2-variants-of-concern-and-variants-of-interest

3. Data Analysis Team Epidemiological Investigation and Analysis Task Force Central Disease Control Headquarters Korea Disease Control and Prevention Agency (KDCA). Outbreak report of COVID‐19 during designation of class 1 infectious disease in the Republic of Korea (January 20 2020–April 24 2022).2023. Accessed August 8 2022. https://www.kdca.go.kr/board/board.es?mid=a20602010000&bid=0034&list_no=720267&act=view

4. Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections

5. Importation and Transmission of SARS-CoV-2 B.1.1.529 (Omicron) Variant of Concern in Korea, November 2021